- Home
- MURA vs TELA Comparison
MURA vs TELA Comparison
Compare MURA & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- TELA
- Stock Information
- Founded
- MURA 2013
- TELA 2012
- Country
- MURA Ireland
- TELA United States
- Employees
- MURA N/A
- TELA N/A
- Industry
- MURA
- TELA Medical/Dental Instruments
- Sector
- MURA
- TELA Health Care
- Exchange
- MURA Nasdaq
- TELA Nasdaq
- Market Cap
- MURA 62.2M
- TELA 61.8M
- IPO Year
- MURA N/A
- TELA 2019
- Fundamental
- Price
- MURA $3.49
- TELA $3.07
- Analyst Decision
- MURA Strong Buy
- TELA Strong Buy
- Analyst Count
- MURA 4
- TELA 4
- Target Price
- MURA $16.00
- TELA $9.25
- AVG Volume (30 Days)
- MURA 50.8K
- TELA 420.8K
- Earning Date
- MURA 11-13-2024
- TELA 11-07-2024
- Dividend Yield
- MURA N/A
- TELA N/A
- EPS Growth
- MURA N/A
- TELA N/A
- EPS
- MURA N/A
- TELA N/A
- Revenue
- MURA N/A
- TELA $68,649,000.00
- Revenue This Year
- MURA N/A
- TELA $30.39
- Revenue Next Year
- MURA N/A
- TELA $25.29
- P/E Ratio
- MURA N/A
- TELA N/A
- Revenue Growth
- MURA N/A
- TELA 29.34
- 52 Week Low
- MURA $2.88
- TELA $2.30
- 52 Week High
- MURA $6.25
- TELA $7.84
- Technical
- Relative Strength Index (RSI)
- MURA 51.24
- TELA 63.33
- Support Level
- MURA $3.31
- TELA $2.90
- Resistance Level
- MURA $3.66
- TELA $3.20
- Average True Range (ATR)
- MURA 0.17
- TELA 0.18
- MACD
- MURA -0.01
- TELA 0.03
- Stochastic Oscillator
- MURA 54.55
- TELA 76.15
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About TELA TELA Bio Inc.
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.